The U.S. Patent Office has granted CollPlant Ltd a patent covering processing methods for making human collagen from plants. Collagen is the most common protein in the human body. CollPlant’s technology is based on the production of human collagen through the genetic engineering of tobacco plants by implanting five genes in them that are found in the connective tissues of the human body.
According to its press release, the company is developing a range of solutions that include products to treat the inflammation of tendons, of chronic wounds among diabetic patients and a bone graft substitute for bone healing.
Besides the U.S. Patent Office, countries that have granted patents for CollPlant’s core technology are: the European Union, China, Japan, Australia, South Africa, India, Mexico, New Zealand and Singapore. CollPlant, established in Israel in 2004, is focused on advancing regenerative medicine
Company CEO Yehiel Tal said, “The USA is one of the company’s strategic target markets, and we see the strengthening of our intellectual property in this territory as a significant achievement.
